154 related articles for article (PubMed ID: 12006142)
1. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique.
Warren S; Taylor G; Smith J; Buck H; Parry-Billings M
J Aerosol Med; 2002; 15(1):15-25. PubMed ID: 12006142
[TBL] [Abstract][Full Text] [Related]
2. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
[TBL] [Abstract][Full Text] [Related]
3. Lung deposition of budesonide from the novel dry powder inhaler Airmax.
Hirst RH; Newman SR; Clark DA; Hertog MG
Respir Med; 2002 Jun; 96(6):389-96. PubMed ID: 12117037
[TBL] [Abstract][Full Text] [Related]
4. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
Lähelmä S; Kirjavainen M; Kela M; Herttuainen J; Vahteristo M; Silvasti M; Ranki-Pesonen M
Br J Clin Pharmacol; 2005 Feb; 59(2):167-73. PubMed ID: 15676038
[TBL] [Abstract][Full Text] [Related]
5. Scintigraphic evaluation of lung deposition with a novel inhaler device.
Newman SP; Hirst PH; Pitcairn GR
Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S12-4. PubMed ID: 11385810
[TBL] [Abstract][Full Text] [Related]
6. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
Pitcairn G; Reader S; Pavia D; Newman S
J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
[TBL] [Abstract][Full Text] [Related]
7. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
Munzel U; Marschall K; Fyrnys B; Wedel M
Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
[TBL] [Abstract][Full Text] [Related]
8. Assessment of adrenal suppression from two new dry powder inhaler formulations of budesonide delivered by Clickhaler compared with the Pulmicort Turbuhaler.
Kirkpatrick C; Buck H; Ellis S
J Aerosol Med; 2003; 16(1):31-6. PubMed ID: 12737682
[TBL] [Abstract][Full Text] [Related]
9. Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder.
Duddu SP; Sisk SA; Walter YH; Tarara TE; Trimble KR; Clark AR; Eldon MA; Elton RC; Pickford M; Hirst PH; Newman SP; Weers JG
Pharm Res; 2002 May; 19(5):689-95. PubMed ID: 12069174
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
[TBL] [Abstract][Full Text] [Related]
11. Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge.
Lipworth BJ; Sims EJ; Das SK; Buck H; Paterson M
Ann Allergy Asthma Immunol; 2005 Jun; 94(6):675-81. PubMed ID: 15984601
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of budesonide delivered by the clickhaler® and turbuhaler® dry powder inhalers in healthy volunteers : a pilot study.
Godfrey C; Buck H; Ellis S
Clin Drug Investig; 2002; 22(2):119-24. PubMed ID: 23315399
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of budesonide Clickhaler and Turbuhaler in adult asthma.
Morice A; Das S; Ellis S;
J Asthma; 2005 Oct; 42(8):697-703. PubMed ID: 16266962
[TBL] [Abstract][Full Text] [Related]
14. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma.
Bisgaard H; Klug B; Sumby BS; Burnell PK
Eur Respir J; 1998 May; 11(5):1111-5. PubMed ID: 9648964
[TBL] [Abstract][Full Text] [Related]
15. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
Chrystyn H; Safioti G; Keegstra JR; Gopalan G
Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort.
Pitcairn GR; Lankinen T; Seppälä OP; Newman SP
J Aerosol Med; 2000; 13(2):97-104. PubMed ID: 11010599
[TBL] [Abstract][Full Text] [Related]
17. Deposition patterns with Turbuhaler.
Borgström L
J Aerosol Med; 1994; 7(Suppl 1):S49-53. PubMed ID: 10147081
[TBL] [Abstract][Full Text] [Related]
18. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects.
Borgström L; Bondesson E; Morén F; Trofast E; Newman SP
Eur Respir J; 1994 Jan; 7(1):69-73. PubMed ID: 8143834
[TBL] [Abstract][Full Text] [Related]
19. A dry powder inhaler with reduced mouth-throat deposition.
Wang ZL; Grgic B; Finlay WH
J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
[TBL] [Abstract][Full Text] [Related]
20. Lung deposition from the Turbuhaler in children with cystic fibrosis.
Devadason SG; Everard ML; MacEarlan C; Roller C; Summers QA; Swift P; Borgstrom L; Le Souëf PN
Eur Respir J; 1997 Sep; 10(9):2023-8. PubMed ID: 9311496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
